Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 253-261
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.253
Table 1 Clinical trials of immune therapy in hepatocellular carcinoma
RegimenPatients, nClinical responseReference
HCC vaccines
DC's + auto-tumor lysate31PR: 12.9%, SD: 54.8%Lee et al[53], 2005
DC's + 4 AFP peptides16No clinical responseButterfield et al[30], 2007
DC's + HepG2 lysate25PR + SD: 28%Palmer et al[52], 2009
GV 1001 + GM-CSF40SD: 45.9%Greten et al[71], 2010
GPC3 peptides33PR: 3%, SD: 57.6%Sawada et al[72], 2012
DC's30PR: 17%, SD: 60%El Ansary et al[49], 2013
Immune checkpoint inhibitors
Tremelimumab21PR: 17.6%, SD: 58.8%Sangro et al[62], 2013